1 Growth Stock Down 45% to Buy Right Now, According to Wall Street

Ladies and gentlemen, buckle up! We're diving into the world of growth stocks, and today, we've got a gem that's been beaten down but is ready to shine. DexCom (DXCM) has taken a 45% hit, but don't let that fool you—this stock is a BUY NOW! Let's break it down.



First things first, why the decline? The market's been spooked by the rise of GLP-1 agonist drugs, which are making waves in diabetes management. But here's the thing: these drugs don't replace the need for continuous glucose monitoring (CGM) devices. In fact, they complement them! DexCom's CGMs provide real-time data that's crucial for effective diabetes management. So, the fear is overblown, and the opportunity is HUGE!

Now, let's talk numbers. DexCom's financials are rock solid. In the second quarter of 2024, they delivered 15% year-over-year revenue growth to $1 billion, and their net income soared by 24% to $143.5 million. They've got $3.1 billion in cash and investments, and their revolving-credit facility is unused. This is a company with a strong financial foundation and the resources to innovate and grow.

And grow they have! DexCom recently launched the first-ever, over-the-counter glucose biosensor approved in the U.S., called Stelo. This opens up a massive new market for them, and it's just the beginning. The company's top and bottom lines are still in good shape, and they're continuing to roll out new products and expand their growth story.



But don't just take my word for it. Wall Street is all over this stock. The Wall Street Journal tracks 45 analysts who cover DexCom, and 27 of them have assigned it the highest possible buy rating. That's right—Wall Street is screaming BUY! And with good reason. DexCom maintains a considerable market share of the vast and growing multibillion-dollar addressable CGM industry. This is a company with a bright future, and now is the time to get in.

So, what are you waiting for? The market's been volatile, with the US Investor Sentiment, % Bullish, at 40.96% and CNN’s Fear & Greed Index in “extreme fear” territory. But that's all the more reason to snap up a growth stock like DexCom while it's on sale. This is a no-brainer! DexCom is a buy, and you need to own this stock NOW! Don't miss out on this opportunity to get in on the ground floor of a company that's poised for growth. BOO-YAH! This stock's a winner!